Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Senores Pharmaceuticals Ltd (SENORES)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 544319 NSE: SENORES Pharmaceuticals & Drugs | Small Cap | Senores Pharmaceutic Share Price
₹1,467.45 4.85 (0.33%)
As on 11-Sep'26 16:59
Senores Pharmaceuticals Ltd (SENORES)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 544319 NSE: SENORES Pharmaceuticals & Drugs | Small Cap | Senores Pharmaceutic Share Price
₹1,467.45 4.85 (0.33%)
As on 11-Sep'26 16:59
Key Metrics
Valuation Multiples
Market Cap
₹6,758 Cr.
Current Price
₹1,467.5
52-Week Low / High
₹662 / 1,600
TTM EPS
₹27.4
TTM Sales
₹674 Cr.
Book Value per Share
₹209.3
P/E Ratio
53.48
Lower than its 5-year historical median
Industry PE
54.2
Price to Book (P/B)
7.01
Higher than its 5-year historical median
Price to Sales (P/S)
10.03
Lower than its 5-year historical median
EV/EBITDA
29.54
Lower than its 5-year historical median
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
14.14%
Outperforms industry median
Return on Capital Employed (ROCE)
15.66%
Outperforms industry median
Return on Assets (ROA)
8.64%
Operating Profit Margin
26.6%
Net Profit Margin
19.21%
Gross Profit Margin
30.1%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
175.27%
Operating Profit Growth (1 Year)
Slowing versus 3-year growth rate
87.65%
Net Profit Growth (1 Year)
Improving versus 3-year growth rate
108.31%
Asset Quality
Promoter Holding
45.82%
Pledged shares (%) of Promoter's holding (%)
2.81%
Reserves
₹918 Cr.
Equity
₹46.1 Cr.
Face Value
₹10
All Time Low / High
₹440.00 / 1599.55
Check Before You Invest
Quality
Not GoodValuation
OvervaluedCheck Valuation charts
Price Trend
Semi Strong
Is Senores Pharmaceuticals Ltd a good quality company?
Senores Pharmaceuticals Ltd is a weak quality company, based on a inconsistent multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Senores Pharmaceuticals Ltd performance compare with that of its Peers?
Revenue growth of Senores Pharmaceuticals Ltd vs industry peers?
Senores Pharmaceuticals Ltd revenue CAGR is 0.00%, compared to the industry median CAGR of 0.00%, indicating stable growth and maintaining its market share.
Promoter shareholding and pledge status of Senores Pharmaceuticals Ltd?
Promoters hold 45.82% of the Senores Pharmaceuticals Ltd, with 2.81% of their stake pledged, indicating low pledge risk.
Stock return of Senores Pharmaceuticals Ltd over the last decade?
Over the last 1 year(s), the stock has delivered a CAGR of 113.03% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Senores Pharmaceuticals Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good
Value Creation ⓘ
| Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|
| ROCE % ⓘ | 2.9% | 5.5% | 2.6% | 2.2% | 4.2% | - |
| Value Creation Index ⓘ | -0.8 | -0.6 | -0.8 | -0.8 | -0.7 | - |
Growth Parameters ⓘ |
||||||
| Sales ⓘ | 13.5 | 12.4 | 34 | 38.5 | 106 | 101 |
| Sales YoY Gr. | - | -8.6% | 174.7% | 13.3% | 175.3% | - |
| Adj EPS ⓘ | 0.6 | -1.2 | 0.1 | 0.3 | 0.1 | 4 |
| YoY Gr. | - | -314% | NA | 138.5% | -61.3% | - |
| BVPS (₹) ⓘ | 38.5 | 39.7 | 55.1 | 153.7 | 162.8 | 163 |
| Adj Net Profit ⓘ | 0.5 | -1.2 | 0.4 | 1.4 | 0.6 | 19 |
| Cash Flow from Ops. ⓘ | -24.1 | -43.4 | -62.8 | -20.4 | -26.9 | - |
| Debt/CF from Ops. ⓘ | -0.6 | -1.4 | -1.5 | -4.6 | -2.7 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | NA | NA | 104.6% | 175.3% | ||||
| Adj EPS ⓘ | NA | NA | NA | -61.3% | ||||
| BVPSⓘ | NA | NA | 60.1% | 5.9% | ||||
| Share Price | - | - | - | 114.8% | ||||
Key Financial Parameters ⓘ
| Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 1.5 | -3.3 | 0.4 | 0.3 | 0.1 | 2.5 |
| Op. Profit Mgn % ⓘ | 8.5 | -14.4 | -0.2 | -18.9 | -17.6 | -5.1 |
| Net Profit Mgn % ⓘ | 3.7 | -9.7 | 1.1 | 3.7 | 0.5 | 18.4 |
| Debt to Equity ⓘ | 0.4 | 1.6 | 0.6 | 0.1 | 0.1 | - |
| Working Cap Days ⓘ | 0 | 1,783 | 1,262 | 2,047 | 1,302 | 449 |
| Cash Conv. Cycle ⓘ | 0 | 311 | 157 | 196 | 142 | 344 |
Valuation of Senores Pharmaceutic - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.90 | 1.90 | 2.81 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|
| Sales | 14 | 35 | 215 | 398 | 633 |
| Operating Expenses ⓘ + | 12 | 23 | 173 | 309 | 464 |
| Operating Profit ⓘ | 2 | 13 | 42 | 90 | 168 |
| Operating Profit Margin (%) | 13.8% | 35.9% | 19.4% | 22.5% | 26.6% |
| Other Income ⓘ + | 0 | 4 | 3 | 19 | 47 |
| Interest ⓘ | 1 | 2 | 9 | 22 | 25 |
| Depreciation ⓘ | 1 | 2 | 10 | 17 | 31 |
| Profit Before Tax ⓘ | 1 | 12 | 25 | 71 | 159 |
| Tax ⓘ | 0 | 4 | -8 | 12 | 38 |
| Profit After Tax | 1 | 8 | 33 | 58 | 122 |
| PAT Margin (%) | 7.0% | 23.9% | 15.3% | 14.7% | 19.2% |
| Adjusted EPS (₹) | 1.1 | 8.6 | 10.3 | 12.7 | 25.1 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0% | 0% |
| PARTICULARS | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 37 | 45 | 204 | 786 | 933 | ||||||
| Debt + | 14 | 38 | 166 | 194 | 224 | ||||||
| Minority Interest | 0 | 0 | 27 | 26 | 31 | ||||||
| Trade Payables | 7 | 14 | 113 | 67 | 235 | ||||||
| Others Liabilities ⓘ | 1 | 34 | 96 | 135 | 181 | ||||||
| Total Liabilities ⓘ | 59 | 131 | 607 | 1,208 | 1,604 | ||||||
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 7 | 27 | 235 | 301 | 499 | ||||||
| CWIP ⓘ | 8 | 34 | 97 | 173 | 249 | ||||||
| Investments ⓘ | 15 | 16 | 0 | 0 | 4 | ||||||
| Inventories | 3 | 3 | 37 | 57 | 89 | ||||||
| Trade Receivables | 20 | 22 | 112 | 124 | 325 | ||||||
| Cash Equivalents | 3 | 0 | 13 | 386 | 160 | ||||||
| Others Assets ⓘ | 3 | 28 | 112 | 169 | 278 | ||||||
| Total Assets ⓘ | 59 | 131 | 607 | 1,208 | 1,604 | ||||||
| PARTICULARS | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | -10 | -1 | -26 | -46 | 62 |
| Cash Flow From Investing Activity ⓘ + | -24 | -48 | -54 | -429 | -121 |
| Cash Flow From Financing Activity ⓘ + | 36 | 46 | 87 | 573 | -1 |
| Net Cash Flow ⓘ | 2 | -3 | 7 | 98 | -60 |
| PARTICULARS | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 2.71 | 20.55 | 26.19 | 11.78 | 14.14 | |||||
| ROCE (%) | 3.36 | 18.56 | 12.31 | 11.94 | 15.66 | |||||
| Asset Turnover Ratio | 0.24 | 0.37 | 0.58 | 0.44 | 0.45 | |||||
| PAT to CFO Conversion(x) | -10 | -0.13 | -0.79 | -0.79 | 0.51 | |||||
| Working Capital Days | ||||||||||
| Receivable Days | 505.70 | 215.60 | 114.10 | 108.10 | 129.40 | |||||
| Inventory Days | 76.80 | 31.50 | 34.50 | 43.10 | 42.10 | |||||
| Payable Days | 324.20 | 296.20 | 217.70 | 182 | 219 | |||||
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Senores Pharmaceuticals Ltd FAQs
The current trading price of Senores Pharmaceutic on 11-Sep-2026 16:59 is ₹1,467.5.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 10-Sep-2026 the market cap of Senores Pharmaceutic stood at ₹6,758.1 Cr
The latest P/E ratio of Senores Pharmaceutic as of 10-Sep-2026 is 363.5.
The latest P/B ratio of Senores Pharmaceutic as of 10-Sep-2026 is 9.00.
The 52-week high of Senores Pharmaceutic is ₹1,599.6 and the 52-week low is ₹661.6.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Senores Pharmaceutic is ₹101 ( Cr.) .
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Senores Pharmaceuticals Ltd is a below average quality company.
The key valuation ratios of Senores Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Senores Pharmaceuticals Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.
About Senores Pharmaceuticals Ltd
Senores Pharmaceuticals Limited was originally incorporated as ‘Senores Pharmaceuticals Private Limited’ under the Companies Act, 2013 through certificate of incorporation dated December 26, 2017, issued by the Registrar of Companies, Central Registration Centre. The name of the Company was thereafter changed to ‘Senores Pharmaceuticals Limited’ upon conversion to a public limited company pursuant to a Board resolution dated August 1, 2023, a special resolution passed in the extraordinary general meeting of the Shareholders held on August 24, 2023 and the approval of the central government dated September 4, 2023, and consequently a fresh certificate of incorporation dated September 4, 2023, was issued by the RoC to reflect the change in name.
Senores Pharmaceuticals is global research driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the Regulated Markets of US, Canada and United Kingdom across various therapeutic areas and dosage forms, with a presence in Emerging Markets. Its strength lies in identifying, developing and manufacturing a diverse range of specialty, underpenetrated and complex pharmaceutical products establishing it as a preferred partner to certain customers. Through data analytics, research, market assessment and experienced management, it strategically identifies commercially underpenetrated molecules to launch products in the Regulated and Emerging Markets.
It leverages its R&D capabilities to develop and manufacture a portfolio of differentiated complex pharmaceutical products. Its focus on quality and its ability to identify specialty and complex molecules has resulted in a pipeline of curated complex products spanning diverse dosage forms and therapeutic domains, demonstrated through its partnerships in the Regulated Markets of US, Canada and United Kingdom with foreign and Indian pharmaceutical companies.
Products of the company
Marketed Products
ANDA Products
- Acetaminophen Butalbital and Acetaminophen Butalbital Caffeine
- Chlorzoxazone
- Diclofenac potassium
- Ketorolac
- Mexiletine Hydrochloride
Sourced Products
Awards, accreditations and recognitions
- 2022: Its subsidiary, RPPL, obtained the ISO 9001:2015 certification in the ‘general’ section.
- 2022: Its Subsidiary, RPPL, obtained the ISO 9001:2015 certification in the ‘B-lactum’ section.
- 2023: Its Subsidiary, RPPL, received the WHO-GMP certificate from the FDA in the ‘manufacturer’ category.
- 2023: Its Subsidiary, RPPL, received the GLP certificate from the FDA.
- 2024: The Atlanta Facility of its Subsidiary, Havix, was audited and approved by the USFDA.
History and milestones
- 2021: Incorporated a wholly owned subsidiary, Senores Pharmaceuticals Inc in the US.
- 2021: Entered into a new segment of API with acquisition of Ratnagene Lifescience Private Limited.
- 2022: Started the domestic business with a launch of the critical care injectables.
- 2023: Acquired majority stake in Havix., making it a Subsidiary of the company
- 2023: Consolidated its presence in emerging markets by acquiring shares in Ratnatris Pharmaceuticals Private Limited, making a subsidiary of the company.
- 2024: Launched first CMO product in the US with Jubilant Cadista.
You have 49 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
